Medical Congress

American College of Cardiology Annual Scientific Session 2026

DateMar 28–30, 2026
VenueErnest N. Morial Convention Center
ACC.26
Event DetailsACC.26
Dates
Mar 28–30, 2026
Full Address
Ernest N. Morial Convention Center
Ernest N. Morial Convention CenterOpen in Maps ↗
Congress Prep Guide

Attending ACC.26?

Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.

Use your work or institutional email address.

Free. No spam. Unsubscribe anytime.

Official Registration

Visit Official Website ↗

Strategic Context

This event offers an unparalleled opportunity to connect with peers from around the world, explore the latest advances in cardiovascular medicine, and gain practical insights to improve daily practice. Attendees can learn how new treatments and clinical guidelines impact patient care, engage in meaningful discussions with leading experts, and build lasting professional relationships.

Who Attends

Cardiovascular Professionals, Cardiologists, Clinical Researchers, Healthcare Professionals

Coverage from ACC.26

IVUS Guidance Improves PCI Outcomes in Complex Bifurcation Lesions
Coronary Artery Disease
ACC.26

IVUS Guidance Improves PCI Outcomes in Complex Bifurcation Lesions

Intravascular ultrasound (IVUS) guidance for percutaneous coronary intervention (PCI) in complex bifurcation lesions demonstrated superior outcomes compared to angiography guidance.

SURVIV: Transcatheter Valve-in-Valve Non-Inferior to Redo-Surgery for Mitral Bioprosthetic Dysfunction
Valvular Heart Diseases
ACC.26

SURVIV: Transcatheter Valve-in-Valve Non-Inferior to Redo-Surgery for Mitral Bioprosthetic Dysfunction

The SURVIV trial found transcatheter mitral valve-in-valve implantation non-inferior to redo-surgery for bioprosthetic dysfunction, with similar 1-year mortality.

TRI-FR Trial: Tricuspid Repair Sustains Benefit at Two Years
Valvular Heart Diseases
ACC.26

TRI-FR Trial: Tricuspid Repair Sustains Benefit at Two Years

Two-year outcomes from the TRI-FR trial demonstrate sustained efficacy of transcatheter tricuspid repair without cross-over for severe tricuspid regurgitation.

ALL-RISE: Angiography-Derived Physiology Non-Inferior to Pressure Wire for PCI
Coronary Artery Disease
ACC.26

ALL-RISE: Angiography-Derived Physiology Non-Inferior to Pressure Wire for PCI

The ALL-RISE trial demonstrates non-inferiority of angiography-derived coronary physiology compared to invasive pressure wire guidance for PCI outcomes.

ORBITA-CTO: CTO PCI Offers No Angina Relief Over Placebo
Coronary Artery Disease
ACC.26

ORBITA-CTO: CTO PCI Offers No Angina Relief Over Placebo

The ORBITA-CTO trial found no significant difference in angina symptom improvement between CTO PCI and a placebo procedure.

TRISCEND II: Transcatheter Tricuspid Valve Replacement Two-Year Outcomes
Valvular Heart Diseases
ACC.26

TRISCEND II: Transcatheter Tricuspid Valve Replacement Two-Year Outcomes

Two-year data from TRISCEND II show sustained improvements in severe tricuspid regurgitation with transcatheter valve replacement.

Reverse-FALLS Protocol Reduces Pulmonary Congestion in CPE Patients
Coronary Artery Disease
ACC.26

Reverse-FALLS Protocol Reduces Pulmonary Congestion in CPE Patients

A prospective observational study demonstrated that the Reverse-FALLS protocol effectively reduced pulmonary congestion in patients with cardiogenic pulmonary edema.

CHIP-BCIS3: LV Unloading Trial for High-Risk PCI
Coronary Artery Disease
ACC.26

CHIP-BCIS3: LV Unloading Trial for High-Risk PCI

The CHIP-BCIS3 trial investigated percutaneous left ventricular unloading during high-risk coronary intervention, addressing a critical gap in managing complex PCI patients.

FFR or 3D-QCA Guided Revascularisation: The FAST III Trial
Coronary Artery Disease
ACC.26

FFR or 3D-QCA Guided Revascularisation: The FAST III Trial

The FAST III trial, reported at ACC.26, investigated revascularisation guided by FFR versus 3D-QCA-based vessel-FFR.

HOST-EXAM: Clopidogrel Monotherapy Non-Inferior to Aspirin at 10 Years
Coronary Artery Disease
ACC.26

HOST-EXAM: Clopidogrel Monotherapy Non-Inferior to Aspirin at 10 Years

The HOST-EXAM trial's 10-year follow-up indicates clopidogrel monotherapy is non-inferior to aspirin monotherapy in stable CAD post-PCI with DES.

CHAMPION-AF: LAA Closure Non-Inferior to OAC for AF Outcomes
Atrial Fibrillation
ACC.26

CHAMPION-AF: LAA Closure Non-Inferior to OAC for AF Outcomes

The CHAMPION-AF trial demonstrates left atrial appendage closure is non-inferior to oral anticoagulation for composite thrombotic and bleeding events in atrial fibrillation.

Sex Differences in MINOCA Causes Identified by OCT and CMR Imaging
Myocardial Infarction
ACC.26

Sex Differences in MINOCA Causes Identified by OCT and CMR Imaging

OCT and CMR imaging reveal distinct sex-specific underlying causes of myocardial infarction with no obstructive coronary arteries (MINOCA).

PRO-TAVI: Deferring PCI Before TAVI Non-Inferior to Routine PCI
Aortic Valve Stenosis
ACC.26

PRO-TAVI: Deferring PCI Before TAVI Non-Inferior to Routine PCI

The PRO-TAVI trial demonstrated that deferring percutaneous coronary intervention (PCI) before transcatheter aortic valve implantation (TAVI) is non-inferior to routine PCI.

IVUS-Guided PCI Reduces MACE in Left Main Disease: OPTIMAL Trial
Coronary Artery Disease
ACC.26

IVUS-Guided PCI Reduces MACE in Left Main Disease: OPTIMAL Trial

The OPTIMAL trial demonstrates IVUS-guided PCI significantly reduces major adverse cardiac events compared to angiography-guided PCI in unprotected left main coronary artery disease.

Emboliner Non-Inferior to Sentinel for TAVR Cerebral Protection
Aortic Valve Stenosis
ACC.26

Emboliner Non-Inferior to Sentinel for TAVR Cerebral Protection

ACC.26 trial shows Emboliner embolic protection catheter is non-inferior to Sentinel system during TAVR for preventing cerebral lesions.

DISCOVER INOCA Defines Vasomotor Disorders in Nonobstructive CAD
Coronary Artery Disease
ACC.26

DISCOVER INOCA Defines Vasomotor Disorders in Nonobstructive CAD

The DISCOVER INOCA registry provides a comprehensive definition of coronary vasomotor disorders in patients with ischemia and nonobstructive coronary arteries (INOCA).

Primary LV Unloading in Anterior STEMI Shows No Benefit in STEMI-Door to Unload Trial
Myocardial Infarction
ACC.26

Primary LV Unloading in Anterior STEMI Shows No Benefit in STEMI-Door to Unload Trial

The STEMI-Door to Unload trial found no benefit for primary left ventricular unloading in anterior STEMI without cardiogenic shock.

    0:00 / 0:00